Role of the Serotonin 5-HT2A Receptor in Learning John A. Harvey Learning & Memory, 2003, 355-362 www.learnmem.org http://www.learnmem.org/cgi/doi/10.1101/lm.60803. This study reviews the role of the serotonin 5-HT2A receptor in learning as measured by the acquisition of the rabbit’s classically conditioning nictitating membrane response, a component of the eyeblink response. Agonists at the 5-HT2A receptor including LSD (d-lysergic acid diethylamide) enhanced associative learning at doses that produce cognitive effects in humans. Some antagonists such as BOL (d-bromolysergic acid diethylamide), LY53,857, and ketanserin acted as neutral antagonists in that they had no effect on learning, whereas others (MDL11,939, ritanserin, and mianserin) acted as inverse agonists in that [...]
Lire la suiteThe Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders Franz X. VOLLENWEIDER & Michael KOMETER Nature Reviews Neuroscience, 2010, 11, (9), 642-51 DOI: 10.1038/nrn2884 Abstract After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical [...]
Lire la suitePsychedelics and Mental Health : A Population Study Teri S. Krebs, Pal-Ørjan Johansen PLoS ONE, 2013, 8, (8): e63972. doi:10.1371/journal.pone.0063972 Abstract Background : The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. Objective : To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. Method : Data drawn from years 2001 [...]
Lire la suiteThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future Robin L Carhart-Harris and Guy M Goodwin Neuropsychopharmacology, 2017, 42, 2105–2113 doi:10.1038/npp.2017.84; published online 17 May 2017 Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady [...]
Lire la suite'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]
Lire la suiteEvidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955 Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]
Lire la suiteIntercultural, intermolecular : An ethnobotanical examination of the potential therapeutic value of LSD for the treatment of depression Karsten FATUR Journal of Psychedelic Studies, 2019, 3, (1), 32–34. DOI: 10.1556/2054.2019.002 Lysergic acid diethylamide holds great therapeutic potential in the treatment of depression, although currently illegal in many parts of the world and seen as a recreational drug. An intercultural ethnobotanical examination of plant substances with similar chemical profiles and effects displays the true potential value of this substance and justifies an increased focus on clinical trials and studies involving it. Keywords : psychedelic, LSD, ayahuasca, depression, serotonin Despite its current status as an illegal substance, lysergic [...]
Lire la suiteNeural correlates of the LSD experience revealed by multimodal neuro-imagerie Robin L. Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E. Schenberg, Timothy Nest, Csaba Orban, Robert Leech, Luke T. Williams, Tim M. Williams, Mark Bolstridge, Ben Sessa, John McGonigle, Martin I. Sereno, David Nichols, Peter J. Hellyer, Peter Hobden, John Evans, Krish D. Singh, Richard G. Wise, H. Valerie Curran, Amanda Feilding, and David J. Nutt PNAS (Proceedings of The National Academy of Sciences of the USA), 2016, 113, 17, 4853-4858 www.pnas.org/cgi/doi/10.1073/pnas.1518377113 Abstract Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the human [...]
Lire la suiteHow do hallucinogens work on the brain? Robin Carhart-Harris, Mendel Kaelen and David Nutt The Psychologist, 2014, 27, 9, 662-665 What do we know about how hallucinogens work on the brain to produce their characteristic subjective effects? This question can be approached from a number of different levels. At the lowest functionally relevant level, how do the hallucinogenic compounds themselves interact with a certain neurotransmitter receptor to alter neuronal activity? Then at the neuronal population level, how does a drug-induced change in neuronal firing interact with the integrated oscillatory activity of large populations of neurons? Finally, how does this all play out at [...]
Lire la suiteIntérêt de la psilocybine, de l’acide lysergique diéthylamide (LSD) et de la diméthyltryptamine (DMT) dans la dépression : une revue de la littérature THÈSE MÉDECINE SPÉCIALISÉE CLINIQUE en Psychiatrie Présentée et soutenue publiquement par Sami SERGENT le 22 février 2019 ANNÉE 2019 (2019 TOU3 1503) Directeur de thèse : Dr François MONTASTRUC JURY Monsieur le Professeur Christophe ARBUS Président Monsieur le Professeur Laurent SCHMITT Assesseur Monsieur le Professeur Nicolas FRANCHITTO Assesseur Monsieur le Docteur François MONTASTRUC Assesseur Madame le Docteur Bénédicte JULLIAN Suppléant Monsieur le Docteur Nicolas NAVARRO membre invité RESUME EN FRANÇAIS : La psilocybine, l’acide lysergique diéthylamide et la diméthyltryptamine sont des psychédéliques agonistes sérotoninergiques. Les sociétés humaines en font usages depuis [...]
Lire la suite